Pfizer (PFE) Short-Term Debt issuances (2009 - 2026)

Pfizer (PFE) has 18 years of Short-Term Debt issuances data on file, last reported at -$127.0 million in Q1 2026.

• Short-Term Debt issuances for Q1 2026 came in at -$127.0 million, up 67.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $259.0 million (up 106.35% YoY), and the FY2024 annual result was $8.9 billion, up 181.78% from the prior year.
• Short-Term Debt issuances fell to -$127.0 million in Q1 2026 per PFE's latest filing, from $903.0 million in the prior quarter.
• Over five years, Short-Term Debt issuances peaked at $4.2 billion in Q3 2022 and troughed at -$2.6 billion in Q3 2024.
• A 5-year average of $557.1 million and a median of -$127.0 million in 2026 frame the typical range for Short-Term Debt issuances.
• The sharpest annual moves came in 2022 and 2024: Short-Term Debt issuances soared 16828.0% in 2022, then sank 1100.47% in 2024.
• A 5-year view of Short-Term Debt issuances shows it stood at $3.9 billion in 2022, then slipped by 19.04% to $3.1 billion in 2023, then slumped by 182.3% to -$2.6 billion in 2024, then surged by 134.86% to $903.0 million in 2025, then slumped by 114.06% to -$127.0 million in 2026.
• Business Quant data shows PFE's Short-Term Debt issuances at -$127.0 million in Q1 2026, $903.0 million in Q3 2025, and -$517.0 million in Q2 2025.